CAJ | 학술논문

背景与目的:紫杉醇治疗胃癌恶性腹腔积液具有良好的疗效,但临床研究较少.本研究探讨紫杉醇腹腔化疗治疗胃癌恶性腹腔积液的有效性及安全性.方法:6例晚期胃癌伴恶性腹腔积液患者,紫杉醇60 mg/m~2+0.9%氯化钠溶液1 500～2 000 mL腹腔内化疗,每周1次,共2～4周.按WHO标准对疗效及不良反应进行判断.结果:5/6例患者CR,1/6例PR.腹腔积液缓解时间为0.5～10个月,总生存期2～10个月.Ⅰ～Ⅲ度腹痛者4例,Ⅰ度白细胞下降者4例,Ⅰ度脱发者3例,Ⅰ度肝功能损害者1例(既往有乙肝病史).结论:紫杉醇腹腔化疗治疗胃癌恶性腹腔积液相对安全有效.
배경여목적:자삼순치료위암악성복강적액구유량호적료효,단림상연구교소.본연구탐토자삼순복강화료치료위암악성복강적액적유효성급안전성.방법:6례만기위암반악성복강적액환자,자삼순60 mg/m~2+0.9%록화납용액1 500～2 000 mL복강내화료,매주1차,공2～4주.안WHO표준대료효급불량반응진행판단.결과:5/6례환자CR,1/6례PR.복강적액완해시간위0.5～10개월,총생존기2～10개월.Ⅰ～Ⅲ도복통자4례,Ⅰ도백세포하강자4례,Ⅰ도탈발자3례,Ⅰ도간공능손해자1례(기왕유을간병사).결론:자삼순복강화료치료위암악성복강적액상대안전유효.
Background and purpose: Paclitaxel is believed to be efficient in treating malignant ascites in gastric cancer. However, researches are still needed to get more evidence. The aim of this study was to discuss the efficacy and safety of the treatment of malignant ascites in gastric cancer with paclitaxel. Methods: Six cases of late phase gastric cancer patients were enrolled into the study, paclitaxel 60 mg/m~2 and 1 500-2 000 mL natural solution were administered via intraperitoneal injection, qw, for a of total 2-4 weeks. Efficacy and toxicity were determined according to WHO criteria. Results: Five (5/6) had complete response, and one (1/6) with partial response. The malignant ascites recession time was 0.5-10 months, overall survival time 2-10 months, 4 cases suffered grade Ⅰ-Ⅲabdominal pain, 4 cases grade Ⅰ leucopenia, 3 cases grade Ⅰ hair loss, 1 case grade Ⅰ liver injury (with past history of hepatitis). Conclusion: Paclitaxel is effective and relatively safe to treat malignant ascites of gastric cancer.